Superluminal Medicines has filed a notice of an exempt offering of securities to raise $25,679,107.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Superluminal Medicines is raising $25,679,107.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Cony Dcruz played a key role…